03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
23:45 , Aug 17, 2017 |  BC Week In Review  |  Clinical News

ArQule begins Phase I of ARQ 531 in B cell malignancies

ArQule Inc. (NASDAQ:ARQL) began a Phase I trial to evaluate once-daily oral ARQ 531 for 4 weeks in patients with relapsed or refractory B cell malignancies. The trial's dose-escalation first portion will test ARQ 531...